Amgen posts results for terminated acapatamab mCRPC trial; updates MARITIME-PEN and AMG 691 recordsNov 13Weekly roundup, 6 itemsacapatamabAMG-691Updated
Amgen gets Amjevita label update; registers Phase 3 MariTide trial against semaglutideNov 6Weekly roundup, 5 itemsadalimumab-attoAmgenUpdated
Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
Amgen's MariTide cardiovascular outcomes trial surfaces; OASIS pediatric migraine results holdOct 29Weekly roundup, 2 itemsAmgenmaridebart cafraglutideUpdated
Amgen registers Phase 2/3 inebilizumab trial in autoimmune hepatitisOct 16Weekly roundup, 3 itemsAmgenetanerceptUpdated
Amgen registers new Phase 3 maridebart cafraglutide vs. semaglutide trial in type 2 diabetesOct 8Weekly roundup, 3 itemsAMG-513AmgenUpdated
Amgen gets FDA biosimilar supplement approval for RIABNI; posts new evolocumab PK trialOct 2Weekly roundup, 5 itemsAmgenapremilastUpdated
FDA approves label update for TEPEZZA; Amgen registers MariTide bioavailability studySep 23Weekly roundup, 2 itemsAmgenmaridebart cafraglutide
Amgen updates MariTide pipeline, discontinues AMG 513, keeps pressing FDA on TAVNEOSAug 4Quarterly updateAMG-513Amgen
Amgen posts results for three rocatinlimab Phase 3 trials, plus CodeBreak300 and AMG 133 updatesJul 24Weekly roundup, 5 itemsAmgenmaridebart cafraglutide
Amgen registers two Phase 3 extension trials for obesity drug maridebart cafraglutideJul 6Weekly roundup, 2 itemsAmgenmaridebart cafraglutide